Dua Monica M, Jensen Christopher W, Friedland Shai, Worth Patrick J, Poultsides George A, Norton Jeffrey A, Park Walter G, Visser Brendan C
Division of Surgical Oncology, Department of Surgery, Stanford University, Stanford, California.
Division of Surgical Oncology, Department of Surgery, Stanford University, Stanford, California.
J Surg Res. 2018 Nov;231:109-115. doi: 10.1016/j.jss.2018.05.020. Epub 2018 Jun 14.
Severe necrotizing pancreatitis may result in midbody necrosis and ductal disruption leaving an isolated pancreatic tail. The purpose of this study was to characterize outcomes among patients with an isolated tail remnant who underwent transgastric drainage or necrosectomy (endoscopic or surgical) and determine the need for subsequent operative management.
Patients with necrotizing pancreatitis and retrogastric walled-off collections treated by surgical transgastric necrosectomy or endoscopic cystgastrostomy ± necrosectomy between 2009 and 2017 were identified by a retrospective chart review. All available preprocedure and postprocedure imaging was reviewed for evidence of isolated distal pancreatic tail remnants.
Seventy-four patients were included (40 surgical and 34 endoscopic). All the patients in the surgical group underwent laparoscopic transgastric necrosectomy; the endoscopic group consisted of 26 patients for pseudocyst drainage and eight patients for necrosectomy. A disconnected pancreatic tail was identified in 22 (29%) patients (13 laparoscopic and nine endoscopic). After the creation of the "cystgastrostomy," there were no external fistulas despite the viable tail. Of the 22 patients, four patients developed symptoms at a median of 23 months (two, recurrent episodic pancreatitis; two, intractable pain). Two patients (both initially in endoscopic group) ultimately required distal pancreatectomy and splenectomy at 24 and 6 months after index procedure.
Patients with a walled-off retrogastric collection and an isolated viable tail are effectively managed by a transgastric approach. Despite this seemingly "unstable anatomy," the creation of an internal fistula via surgical or endoscopic "cystgastrostomy" avoids external fistulas/drains and the short-term necessity of surgical distal pancreatectomy. A very small subset requires intervention for late symptoms.
严重坏死性胰腺炎可能导致胰腺体部坏死和导管中断,仅留下孤立的胰尾。本研究的目的是描述接受经胃引流或坏死组织清除术(内镜或手术)的孤立胰尾残余患者的预后,并确定后续手术治疗的必要性。
通过回顾性病历审查,确定2009年至2017年间接受手术经胃坏死组织清除术或内镜下囊肿胃造口术±坏死组织清除术治疗的坏死性胰腺炎和胃后包裹性积液患者。对所有可用的术前和术后影像进行审查,以寻找孤立的胰腺远端残余的证据。
纳入74例患者(40例手术治疗,34例内镜治疗)。手术组所有患者均接受了腹腔镜经胃坏死组织清除术;内镜组包括26例行假性囊肿引流的患者和8例行坏死组织清除术的患者。22例(29%)患者发现有分离的胰尾(13例腹腔镜手术,9例内镜手术)。在进行“囊肿胃造口术”后,尽管胰尾存活,但未出现外瘘。22例患者中,4例患者在中位时间23个月时出现症状(2例为复发性胰腺炎;2例为顽固性疼痛)。2例患者(最初均在内镜组)最终在初次手术后24个月和6个月需要行远端胰腺切除术和脾切除术。
胃后包裹性积液且有孤立存活胰尾的患者可通过经胃途径有效治疗管中断,仅留下孤立的胰尾。本研究的目的是描述接受经胃引流或坏死组织清除术(内镜或手术)的孤立胰尾残余患者的预后,并确定后续手术治疗的必要性。
通过回顾性病历审查确定2009年至2017年间接受手术经胃坏死组织清除术或内镜下囊肿胃造口术±坏死组织清除术治疗的坏死性胰腺炎和胃后包裹性积液患者。对所有可用的术前和术后影像进行审查,以寻找孤立的胰腺远端残余的证据。
纳入74例患者(40例手术治疗,34例内镜治疗)。手术组所有患者均接受了腹腔镜经胃坏死组织清除术;内镜组包括26例行假性囊肿引流的患者和八例行坏死组织清除术的患者。22例(29%)患者发现有分离的胰尾(13例腹腔镜手术,9例内镜手术)。在进行“囊肿胃造口术”后,尽管胰尾存活,但未出现外瘘。22例患者中,4例患者在中位时间23个月时出现症状(2例为复发性胰腺炎;2例为顽固性疼痛)。2例患者(最初均在内镜组)最终在初次手术后24个月和6个月需要行远端胰腺切除术和脾切除术。
胃后包裹性积液且有孤立存活胰尾的患者可通过经胃途径有效治疗。尽管存在这种看似“不稳定的解剖结构”,但通过手术或内镜“囊肿胃造口术”建立内瘘可避免外瘘/引流管以及手术远端胰腺切除术的短期必要性。极少数患者需要针对晚期症状进行干预。